The Utility of ERBB4 and RB1 Immunohistochemistry in Distinguishing Chromophobe Renal Cell Carcinoma From Renal Oncocytoma

Tong Sun, Lloyd Hutchinson, Amy G. Zhou, Qingqing Liu, Ediz F. Cosar, Maryann St. Cyr, Nicole Ninteau, Karen Dresser, Liang Cheng, Zhong Jiang, Kristine M. Cornejo

Research output: Contribution to journalArticle

Abstract

Objectives. Differentiating renal oncocytoma (RO) from chromophobe renal cell carcinoma (ChRCC) can occasionally be challenging. We evaluated the expression of RB1 and ERBB4 in RO and ChRCC, and compared the immunohistochemistry (IHC) results to RB1 and ERBB4 gene abnormalities detected by fluorescence in situ hybridization (FISH). Materials and Methods. Fifty-three kidney resections (ChRCC, n=28; RO, n=25) were stained for RB1 and ERBB4 IHC and FISH was performed to evaluate gene copy number analysis. Results. A loss of RB1 staining was identified in 64% (18/28) of ChRCCs, which was not found in any ROs (0/25; P <.001). FISH analysis revealed 36% (10/28) of ChRCCs contained a RB1 hemizygous deletion with a concordance of 56% (10/18) between the IHC and FISH findings. No RB1 gene copy number variations were detected in any of the ROs (0/25; P <.001) and retained expression of RB1 by IHC. ERBB4 showed cytoplasmic/membranous staining in all ROs and ChRCCs. However, 75% (21/28) of ChRCCs also contained nuclear positivity for ERBB4, which was uncommonly seen in ROs (3/25, 12%; P <.001). A hemizygous ERBB4 gene deletion was detected in 46% of ChRCCs (13/28), but none of the ROs (0/25; 0%). Loss of labeling by RB1 or nuclear staining for ERBB4 IHC identified 25 of 28 (89%) of ChRCCs. Conclusion. In summary, the loss of RB1 expression is a highly specific diagnostic biomarker in distinguishing ChRCC from RO. Nuclear ERBB4 expression also appears to be a sensitive diagnostic biomarker for ChRCC, albeit the mechanism is unknown.

Original languageEnglish (US)
Pages (from-to)259-264
Number of pages6
JournalInternational Journal of Surgical Pathology
Volume28
Issue number3
DOIs
StatePublished - May 1 2020

Keywords

  • ERBB4
  • RB1
  • chromophobe renal cell carcinoma
  • fluorescence in situ hybridization
  • immunohistochemistry
  • renal oncocytoma

ASJC Scopus subject areas

  • Anatomy
  • Surgery
  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'The Utility of ERBB4 and RB1 Immunohistochemistry in Distinguishing Chromophobe Renal Cell Carcinoma From Renal Oncocytoma'. Together they form a unique fingerprint.

  • Cite this

    Sun, T., Hutchinson, L., Zhou, A. G., Liu, Q., Cosar, E. F., St. Cyr, M., Ninteau, N., Dresser, K., Cheng, L., Jiang, Z., & Cornejo, K. M. (2020). The Utility of ERBB4 and RB1 Immunohistochemistry in Distinguishing Chromophobe Renal Cell Carcinoma From Renal Oncocytoma. International Journal of Surgical Pathology, 28(3), 259-264. https://doi.org/10.1177/1066896919883016